Glycomet: Advanced Glycemic Control for Type 2 Diabetes
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 180 | $0.21 | $36.98 (0%) | 🛒 Add to cart |
| 270 | $0.18 | $55.47 $49.02 (12%) | 🛒 Add to cart |
| 360 | $0.17
Best per pill | $73.96 $61.06 (17%) | 🛒 Add to cart |
Similar products
Glycomet is a widely prescribed oral antidiabetic medication containing metformin hydrochloride, designed to manage blood glucose levels in patients with type 2 diabetes mellitus. As a first-line therapeutic agent, it functions primarily by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues. Its efficacy, safety profile, and cost-effectiveness have established it as a cornerstone in diabetes management protocols globally. Healthcare providers often recommend Glycomet both as monotherapy and in combination with other antidiabetic agents to achieve optimal glycemic targets.
Features
- Active ingredient: Metformin hydrochloride
- Available in immediate-release and extended-release formulations
- Standard strengths: 500 mg, 850 mg, and 1000 mg tablets
- White to off-white, film-coated, round or oval biconvex tablets
- Bioequivalent to reference listed drugs
- Manufactured under strict pharmaceutical compliance (e.g., GMP)
Benefits
- Effectively lowers fasting and postprandial blood glucose levels
- Reduces risk of diabetes-related complications through sustained glycemic control
- Associated with weight neutrality or modest weight loss, unlike some other antidiabetic agents
- May improve lipid profiles and offer cardiovascular protective benefits
- Does not cause hypoglycemia when used as monotherapy
- Cost-effective with widespread insurance coverage and generic availability
Common use
Glycomet is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. It is used both as initial pharmacotherapy and in combination with other oral antidiabetic agents or insulin when glycemic targets are not met with monotherapy. It may also be used off-label in conditions like polycystic ovary syndrome (PCOS) under specialist supervision.
Dosage and direction
Dosage must be individualized based on efficacy and tolerability, while not exceeding the maximum recommended daily dose of 2550 mg for adults and 2000 mg for pediatric patients. The usual starting dose for Glycomet immediate-release is 500 mg twice daily or 850 mg once daily, taken with meals. Dosage may be increased gradually in increments of 500 mg weekly or 850 mg every two weeks. The extended-release formulation is usually started at 500 mg once daily with the evening meal, with dose escalation guided by glycemic response. Tablets should be swallowed whole and not crushed or chewed.
Precautions
- Renal function should be assessed before initiation and periodically thereafter; use is not recommended when eGFR is below 30 mL/min/1.73m².
- Avoid use in conditions predisposing to renal impairment or hypoxia (e.g., dehydration, acute congestive heart failure, sepsis).
- Temporary discontinuation is advised for procedures involving intravascular iodinated contrast materials due to risk of contrast-induced nephropathy.
- Monitor vitamin B12 levels annually or as clinically indicated; long-term use may lower serum levels.
- Use caution in elderly patients, particularly those ≥80 years, unless renal function is confirmed normal.
Contraindications
- Severe renal impairment (eGFR <30 mL/min/1.73m²)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- History of hypersensitivity to metformin or any component of the formulation
- Acute congestive heart failure requiring pharmacological treatment
Possible side effect
Common adverse reactions (>1%) include diarrhea, nausea, vomiting, flatulence, abdominal discomfort, and indigestion. These often occur during initiation and are usually transient. Lactic acidosis is a rare but serious metabolic complication requiring immediate medical attention. Other less common side effects may include taste disturbance, decreased vitamin B12 absorption, and, very rarely, hepatitis or skin reactions such as erythema or pruritus.
Drug interaction
- Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin) may compete for renal tubular secretion and increase metformin exposure.
- Alcohol potentiates the effect of metformin on lactate metabolism; excessive intake should be avoided.
- Glucocorticoids, diuretics, estrogens, phenothiazines, thyroid products, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid may reduce hypoglycemic effectiveness.
- Beta-blockers, clonidine, lithium, or alcohol may potentiate hypoglycemia.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the usual dosing schedule. Do not double the dose to make up for a missed one.
Overdose
Hypoglycemia has not been reported with metformin overdose alone but may occur when combined with other antidiabetic agents. Lactic acidosis is a medical emergency and may occur in the setting of overdose, especially with concomitant renal impairment or other risk factors. Symptoms include vomiting, diarrhea, hypothermia, hypotension, and acute kidney injury. Management includes supportive care, hemodialysis (which removes metformin), and correction of electrolyte and acid-base imbalances.
Storage
Store at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep in a tightly closed container, protected from light and moisture. Keep out of reach of children and pets.
Disclaimer
This information is intended for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or discontinuing any medication or treatment plan. Individual patient needs and responses may vary.
Reviews
Glycomet is generally well-regarded in the medical community for its efficacy and safety in managing type 2 diabetes. Clinical studies and real-world evidence support its role in reducing HbA1c by approximately 1–2% and its favorable effects on cardiovascular outcomes. Patient reviews often highlight significant improvements in daily glucose readings and quality of life, though gastrointestinal side effects during the initial weeks are commonly reported. Many appreciate the affordability and accessibility of the medication. Always discuss personal experiences and treatment responses with a healthcare professional.